Cytek Biosciences, Inc. (CTKB) — SEC Filings
Cytek Biosciences, Inc. (CTKB) — 33 SEC filings. Latest: 8-K (Nov 5, 2025). Includes 15 8-K, 6 10-Q, 5 SC 13G/A.
View Cytek Biosciences, Inc. on SEC EDGAR
Overview
Cytek Biosciences, Inc. (CTKB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 5, 2025: Cytek Biosciences, Inc. filed an 8-K on November 5, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 47215 Lakeview Boulevard, Fremont, California.
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 2 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Cytek Biosciences, Inc. is neutral.
Filing Type Overview
Cytek Biosciences, Inc. (CTKB) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of CTKB's 24 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $52.293M |
| Net Income | -$5.478M |
| EPS | N/A |
| Debt-to-Equity | 0.18 |
| Cash Position | $93.281M |
| Operating Margin | -17.6% |
| Total Assets | $494.919M |
| Total Debt | $0.655M |
Key Executives
- Dr. John W. King
- Ms. Sarah E. Empey
- Wenbin Jiang, Ph.D.
- Michael Holder
- Dr. Robert J. Massoud
- Dr. David J. Ebersole
Industry Context
Cytek operates in the rapidly evolving cell analysis market, a segment of the broader life sciences and biotechnology industry. The market is characterized by significant investment in research and development, driven by advancements in areas like immunology, oncology, and drug discovery. Key trends include the demand for higher-content, more sensitive, and automated cell analysis solutions. Cytek's FSP technology positions it to capitalize on the need for advanced cell characterization, but it faces competition from established players offering traditional flow cytometry and newer single-cell analysis platforms.
Top Tags
financial-reporting (6) · financials (5) · sec-filing (4) · 10-Q (4) · Revenue Decline (3) · 8-k (3) · financial-condition (2) · results-of-operations (2) · Biotechnology (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $5.478M | Swing from $941K net income in Q3 2024 |
| Net Loss (9 months 2025) | $22.463M | Widened from $15.663M net loss in 9 months 2024 |
| Total Revenue (Q3 2025) | $52.293M | Slight increase from $51.500M in Q3 2024 |
| Product Revenue (Q3 2025) | $38.114M | Decreased by 3.6% from Q3 2024 |
| Service Revenue (Q3 2025) | $14.179M | Increased by 18.6% from Q3 2024 |
| Total Operating Expenses (Q3 2025) | $36.743M | Increased by 10.5% from Q3 2024 |
| General and Administrative Expenses (Q3 2025) | $16.121M | Increased by 47.3% from Q3 2024 |
| Cash and Cash Equivalents (Sep 30, 2025) | $93.281M | Decreased from $98.716M at Dec 31, 2024 |
| Net Cash Used in Operating Activities (9 months 2025) | $3.915M | Shift from $23.382M net cash provided in 9 months 2024 |
| Common Stock Outstanding (Oct 31, 2025) | 127,864,830 | Slight decrease from 129,205,901 at Dec 31, 2024 |
| Total Revenue (Q2 2025) | $44.2M | Decreased from $46.5M in Q2 2024, indicating a 4.9% decline. |
| Net Income (Q2 2025) | -$5.1M | Shifted from a $2.3M net income in Q2 2024 to a net loss, representing a significant profitability downturn. |
| Product Revenue (Q2 2025) | $37.8M | Down from $40.2M in Q2 2024, highlighting a core business segment decline. |
| Service Revenue (Q2 2025) | $6.4M | Slightly increased from $6.3M in Q2 2024, showing a minor positive trend in services. |
| Total Revenue (YTD 2025) | $87.1M | Slightly decreased from $87.4M in YTD 2024, indicating a flat to declining year-to-date performance. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cytek Biosciences, Inc. (CTKB)?
Cytek Biosciences, Inc. has 33 recent SEC filings from Jan 2024 to Nov 2025, including 15 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CTKB filings?
Across 33 filings, the sentiment breakdown is: 2 bearish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cytek Biosciences, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cytek Biosciences, Inc. (CTKB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cytek Biosciences, Inc.?
Key financial highlights from Cytek Biosciences, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CTKB?
The investment thesis for CTKB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cytek Biosciences, Inc.?
Key executives identified across Cytek Biosciences, Inc.'s filings include Dr. John W. King, Ms. Sarah E. Empey, Wenbin Jiang, Ph.D., Michael Holder, Dr. Robert J. Massoud and 1 others.
What are the main risk factors for Cytek Biosciences, Inc. stock?
Of CTKB's 24 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Cytek Biosciences, Inc.?
Forward guidance and predictions for Cytek Biosciences, Inc. are extracted from SEC filings as they are enriched.